Dodge & Cox 13F: Cuts GSK Stake by $521M

Dodge & Cox has reduced its position in GSK (NYSE: GSK) by about 9,854,995 shares, according to the latest Form 13F filing with the SEC. This move cuts the fund's stake by approximately 14.4%, leaving it with 58,662,974 shares valued at around $3.1 billion. The filing reflects holdings as of the reporting period and may not represent the investor's current position.

What Changed in Dodge & Cox's GSK Position

Dodge & Cox trimmed its holdings in GSK from 68,517,969 shares to 58,662,974 shares, a reduction of nearly 10 million shares. This represents a 14.4% decrease in their stake. The value of their position now stands at approximately $3.1 billion.

GSK plc Stock Up 5.3%

Shares of GSK (NYSE: GSK) are trading near $52.86. The company, with a market cap of about $106.6 billion, has a P/E ratio of 14.03 and a forward P/E of 10.16. GSK's stock has seen a 52-week low of $35.45 and a high of $61.70, with a 50-day moving average of $53.10 and a 200-day moving average of $49.77. The stock's beta is relatively low at 0.294, indicating less volatility compared to the market.

Recent Earnings

GSK reported revenues of $32.78 billion with a growth rate of 1.5%. The company achieved a net margin of 17.78% and a return on equity of 40.91%. GSK is expected to release its next earnings report on July 28, 2026.

Dividend

GSK pays an annual dividend of $1.80 per share, offering a yield of 3.41%. The dividend payout ratio is 46.54%, indicating a balanced approach between rewarding shareholders and retaining earnings for growth.

About GSK

GSK plc is a healthcare company based in London, United Kingdom. It specializes in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat diseases worldwide. GSK operates through its Commercial Operations and Total R&D segments and is led by CEO Mr. Luke Victor Miels. The company employs around 66,841 people and has a strategic focus on areas like oncology and respiratory diseases.

Bottom Line

Dodge & Cox's decision to reduce its stake in GSK by 14.4% is noteworthy as it reflects a significant change in their investment strategy. Investors often track these filings to gauge institutional sentiment, but it's important to remember that 13F filings are backward-looking and may not represent the current position. GSK remains a major player in the healthcare sector with a solid dividend yield and robust financials.